The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]

Abstract

Slamet Wardoyo,1 Muhammad Arief Fadillah,2 Hamtini2 1Department of Environmental Health, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia; 2Department of Medical Laboratory Technology, Poltekkes Kemenkes Banten, Tangerang, IndonesiaCorrespondence: Slamet Wardoyo, Tel [phone], Email [email protected]

Keywords

• breast cancer
• endocrine therapy
• cdk inhibitors
• apoptosis
• abemaciclib